Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America..
BACKGROUND: Risk of reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown. We assessed the risk and incidence rate of documented SARS-CoV-2 reinfection in a cohort of laboratory-confirmed cases in Qatar.
METHODS: All SARS-CoV-2 laboratory-confirmed cases with at least 1 polymerase chain reaction-positive swab that was ≥45 days after a first positive swab were individually investigated for evidence of reinfection. Viral genome sequencing of the paired first positive and reinfection viral specimens was conducted to confirm reinfection.
RESULTS: Out of 133 266 laboratory-confirmed SARS-CoV-2 cases, 243 persons (0.18%) had at least 1 subsequent positive swab ≥45 days after the first positive swab. Of these, 54 cases (22.2%) had strong or good evidence for reinfection. Median time between the first swab and reinfection swab was 64.5 days (range, 45-129). Twenty-three of the 54 cases (42.6%) were diagnosed at a health facility, suggesting presence of symptoms, while 31 (57.4%) were identified incidentally through random testing campaigns/surveys or contact tracing. Only 1 person was hospitalized at the time of reinfection but was discharged the next day. No deaths were recorded. Viral genome sequencing confirmed 4 reinfections of 12 cases with available genetic evidence. Reinfection risk was estimated at 0.02% (95% confidence interval [CI], .01%-.02%), and reinfection incidence rate was 0.36 (95% CI, .28-.47) per 10 000 person-weeks.
CONCLUSIONS: SARS-CoV-2 reinfection can occur but is a rare phenomenon suggestive of protective immunity against reinfection that lasts for at least a few months post primary infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 73(2021), 7 vom: 05. Okt., Seite e1830-e1840 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abu-Raddad, Laith J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Epidemiology |
|---|
| Anmerkungen: |
Date Completed 11.10.2021 Date Revised 11.10.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciaa1846 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318803135 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318803135 | ||
| 003 | DE-627 | ||
| 005 | 20231225170123.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciaa1846 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1062.xml |
| 035 | |a (DE-627)NLM318803135 | ||
| 035 | |a (NLM)33315061 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abu-Raddad, Laith J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.10.2021 | ||
| 500 | |a Date Revised 11.10.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. | ||
| 520 | |a BACKGROUND: Risk of reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown. We assessed the risk and incidence rate of documented SARS-CoV-2 reinfection in a cohort of laboratory-confirmed cases in Qatar | ||
| 520 | |a METHODS: All SARS-CoV-2 laboratory-confirmed cases with at least 1 polymerase chain reaction-positive swab that was ≥45 days after a first positive swab were individually investigated for evidence of reinfection. Viral genome sequencing of the paired first positive and reinfection viral specimens was conducted to confirm reinfection | ||
| 520 | |a RESULTS: Out of 133 266 laboratory-confirmed SARS-CoV-2 cases, 243 persons (0.18%) had at least 1 subsequent positive swab ≥45 days after the first positive swab. Of these, 54 cases (22.2%) had strong or good evidence for reinfection. Median time between the first swab and reinfection swab was 64.5 days (range, 45-129). Twenty-three of the 54 cases (42.6%) were diagnosed at a health facility, suggesting presence of symptoms, while 31 (57.4%) were identified incidentally through random testing campaigns/surveys or contact tracing. Only 1 person was hospitalized at the time of reinfection but was discharged the next day. No deaths were recorded. Viral genome sequencing confirmed 4 reinfections of 12 cases with available genetic evidence. Reinfection risk was estimated at 0.02% (95% confidence interval [CI], .01%-.02%), and reinfection incidence rate was 0.36 (95% CI, .28-.47) per 10 000 person-weeks | ||
| 520 | |a CONCLUSIONS: SARS-CoV-2 reinfection can occur but is a rare phenomenon suggestive of protective immunity against reinfection that lasts for at least a few months post primary infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a genetics | |
| 650 | 4 | |a immunity | |
| 650 | 4 | |a reinfection | |
| 700 | 1 | |a Chemaitelly, Hiam |e verfasserin |4 aut | |
| 700 | 1 | |a Malek, Joel A |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Ayeda A |e verfasserin |4 aut | |
| 700 | 1 | |a Mohamoud, Yasmin A |e verfasserin |4 aut | |
| 700 | 1 | |a Younuskunju, Shameem |e verfasserin |4 aut | |
| 700 | 1 | |a Ayoub, Houssein H |e verfasserin |4 aut | |
| 700 | 1 | |a Al Kanaani, Zaina |e verfasserin |4 aut | |
| 700 | 1 | |a Al Khal, Abdullatif |e verfasserin |4 aut | |
| 700 | 1 | |a Al Kuwari, Einas |e verfasserin |4 aut | |
| 700 | 1 | |a Butt, Adeel A |e verfasserin |4 aut | |
| 700 | 1 | |a Coyle, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Jeremijenko, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Kaleeckal, Anvar Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Latif, Ali Nizar |e verfasserin |4 aut | |
| 700 | 1 | |a Shaik, Riyazuddin Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Abdul Rahim, Hanan F |e verfasserin |4 aut | |
| 700 | 1 | |a Yassine, Hadi M |e verfasserin |4 aut | |
| 700 | 1 | |a Al Kuwari, Mohamed G |e verfasserin |4 aut | |
| 700 | 1 | |a Al Romaihi, Hamad Eid |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Thani, Mohamed H |e verfasserin |4 aut | |
| 700 | 1 | |a Bertollini, Roberto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 73(2021), 7 vom: 05. Okt., Seite e1830-e1840 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2021 |g number:7 |g day:05 |g month:10 |g pages:e1830-e1840 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciaa1846 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2021 |e 7 |b 05 |c 10 |h e1830-e1840 | ||